Cipla share worth information, Cipla-Eli Lilly Information: Cipla is in talks with US-based Eli Lilly to producer Semaglutide and Ozempic — anti-diabetic drugs — in India, sources instructed Zee Enterprise. The Cipla inventory held on firmly to the inexperienced after the information.
Initially, Eli Lilly will share know-how with Cipla, which is able to later produce these medicine by itself, added the sources.
There’s sturdy demand for Ozempic within the nation.
On the time of publishing this report, queries emailed to Cipla remained unanswered.
Add Zee Enterprise as a Most popular Supply
Cipla share worth information
The Cipla inventory ended increased by Rs 9, or 0.6 per cent, for the day at Rs 1,601.3 apiece on BSE, having gained as a lot as 1.0 per cent to Rs 1,607.6 apiece throughout the session.
The pharma inventory traded with average volumes with about 20,000 shares altering arms for the day on BSE, decrease than a day by day common of 44,000 recorded previously two weeks, in accordance with provisional alternate information.
Cipla shares vs Nifty 50 vs Nifty Pharma
On the present stage, Cipla shares have risen 4.8 per cent up to now in 2025, according to a 5.2 per cent achieve within the Nifty50 although outperforming a 4.7 per cent within the Nifty Pharma.
Cipla Q1 FY26 Outcomes
Final month, the Mumbai-based pharmaceutical agency staged a robust monetary efficiency for the primary quarter of the present monetary 12 months.
Its consolidated internet revenue grew 10.2 per cent to Rs 1,298 crore, beating analysts’ expectations.
ALSO READ: Cipla Q1 FY26 Outcomes | With Rs 1,298 crore Q1 revenue, Mumbai-based pharma firm beats Avenue estimates
How analysts view Cipla shares
Most analysts view Cipla shares positively.
Brokerage Axis Direct has a ‘purchase’ name assigned to the Cipla inventory with a goal worth of Rs 1,700.
At Friday’s closing worth, the goal suggests an upside of 6.8 per cent within the largecap pharma inventory.
